151 related articles for article (PubMed ID: 34103985)
1. Combining Lactate Dehydrogenase and Fibrinogen: Potential Factors to Predict Therapeutic Efficacy and Prognosis of Patients with Small-Cell Lung Cancer.
Huang W; Liu P; Zong M; Chen QQ; Zhou H; Kong H; Xie WP
Cancer Manag Res; 2021; 13():4299-4307. PubMed ID: 34103985
[TBL] [Abstract][Full Text] [Related]
2. Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small-cell lung cancer patients treated with first-line platinum-containing chemotherapy.
He M; Chi X; Shi X; Sun Y; Yang X; Wang L; Wang B; Li H
Thorac Cancer; 2021 Dec; 12(23):3101-3109. PubMed ID: 34725930
[TBL] [Abstract][Full Text] [Related]
3. Correlation analysis of serum cystatin C, uric acid and lactate dehydrogenase levels before chemotherapy on the prognosis of small-cell lung cancer.
Wang H; Shan D; Dong Y; Yang X; Zhang L; Yu Z
Oncol Lett; 2021 Jan; 21(1):73. PubMed ID: 33365084
[TBL] [Abstract][Full Text] [Related]
4. Combining
Lin X; Xiao Z; Hu Y; Zhang X; Fan W
Front Pharmacol; 2020; 11():592768. PubMed ID: 33192532
[No Abstract] [Full Text] [Related]
5. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
Deng M; Ma X; Liang X; Zhu C; Wang M
Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of the serum neuron specific enolase and lactate dehydrogenase in small cell lung cancer patients receiving first-line platinum-based chemotherapy.
Liu X; Zhang W; Yin W; Xiao Y; Zhou C; Hu Y; Geng S
Medicine (Baltimore); 2017 Nov; 96(46):e8258. PubMed ID: 29145241
[TBL] [Abstract][Full Text] [Related]
7. High Systemic Immune-Inflammation Index (SII) Represents an Unfavorable Prognostic Factor for Small Cell Lung Cancer Treated with Etoposide and Platinum-Based Chemotherapy.
Wang C; Jin S; Xu S; Cao S
Lung; 2020 Apr; 198(2):405-414. PubMed ID: 32016563
[TBL] [Abstract][Full Text] [Related]
8. Changes in serum lactate dehydrogenase levels as markers of pathological response and prognosis in colorectal liver metastases patients receiving neoadjuvant chemotherapy followed by resection.
Chen J; Chen Q; Yao J; Jiang Y; Zhou J; Zhao H; Cai J
Ann Palliat Med; 2021 Oct; 10(10):10276-10292. PubMed ID: 34551571
[TBL] [Abstract][Full Text] [Related]
9. Association between serum biomarkers CEA and LDH and response in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
de Jong C; Deneer VHM; Kelder JC; Ruven H; Egberts TCG; Herder GJM
Thorac Cancer; 2020 Jul; 11(7):1790-1800. PubMed ID: 32383328
[TBL] [Abstract][Full Text] [Related]
10. Association between plasma fibrinogen and survival in patients with small-cell lung carcinoma.
Fan S; Guan Y; Zhao G; An G
Thorac Cancer; 2018 Jan; 9(1):146-151. PubMed ID: 29131503
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy.
Ying J; Zhou D; Gu T; Huang J; Liu H
BMC Cancer; 2019 Mar; 19(1):288. PubMed ID: 30925910
[TBL] [Abstract][Full Text] [Related]
12. Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis.
Silvestris N; Scartozzi M; Graziano G; Santini D; Lorusso V; Maiello E; Barni S; Cinieri S; Loupakis F; Pisconti S; Brunetti AE; Palasciano G; Palmieri VO; Del Prete M; Dell'Aquila E; Latiano TP; Petrelli F; Lutrino S; Rossini D; Giampieri R; Lotesoriere C; Cascinu S
Expert Opin Biol Ther; 2015 Feb; 15(2):155-62. PubMed ID: 25411089
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of potential usefulness of serum lactate dehydrogenase level in follow-up of small cell lung cancer.
Chen C; Zhu YH; Huang JA
J Cancer Res Ther; 2018 Jun; 14(Supplement):S336-S340. PubMed ID: 29970686
[TBL] [Abstract][Full Text] [Related]
14. The value of prognostic factors in Chinese patients with small cell lung cancer: A retrospective study of 999 patients.
Hong X; Xu Q; Yang Z; Wang M; Yang F; Gao Y; Zhou F; Wang L; Liu B; Chen G
Clin Respir J; 2018 Feb; 12(2):433-447. PubMed ID: 27460525
[TBL] [Abstract][Full Text] [Related]
15. C-reactive protein and lactate dehydrogenase serum levels potentially predict the response to checkpoint inhibitors in patients with advanced non-small cell lung cancer.
Wei Y; Xu J; Huang X; Xie S; Lin P; Wang C; Guo Y; Zou S; Zhao Z; Wen W; Song Y; Bao Z; Zhang L; Liu W; Kong W; Wang W; He B; Zhang S; Zhou C; Chen Y; Yu Z
J Thorac Dis; 2023 Apr; 15(4):1892-1900. PubMed ID: 37197527
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic factor analysis of patients with unresectablelung squamous cell carcinoma].
Gao X; Li Z; Shao XY; Liu XM; Liu C; Liu YP; Qu XJ; Zhang LY
Zhonghua Zhong Liu Za Zhi; 2021 May; 43(5):569-573. PubMed ID: 34034477
[No Abstract] [Full Text] [Related]
17. The prognostic value of pretreatment albumin-to-fibrinogen ratio in small cell lung cancer patients receiving first-line platinum-based chemotherapy.
Li Q; Li L; Wang Y; Xu C; Zou J
Heliyon; 2023 Sep; 9(9):e19225. PubMed ID: 37662747
[TBL] [Abstract][Full Text] [Related]
18. Impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapy.
Bernhardt D; Aufderstrasse S; König L; Adeberg S; Bozorgmehr F; Christopoulos P; Shafie RAE; Hörner-Rieber J; Kappes J; Thomas M; Herth F; Steins M; Debus J; Rieken S
Cancer Manag Res; 2018; 10():6563-6569. PubMed ID: 30555261
[TBL] [Abstract][Full Text] [Related]
19. Common nutritional/inflammatory indicators are not effective tools in predicting the overall survival of patients with small cell lung cancer undergoing first-line chemotherapy.
Tian H; Li G; Hou W; Jin J; Wang C; Ren P; Wang H; Wang J; Li W; Liu D
Front Oncol; 2023; 13():1211752. PubMed ID: 37576904
[TBL] [Abstract][Full Text] [Related]
20. High score of LDH plus dNLR predicts poor survival in patients with HER2-positive advanced breast cancer treated with trastuzumab emtansine.
Li L; Ai L; Jia L; Zhang L; Lei B; Zhang Q
BMC Cancer; 2022 Jan; 22(1):29. PubMed ID: 34980025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
